Themis Medicare Limited (THEMISMED.BO)
INR 127.95
(6.14%)
INR 127.95
(6.14%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 267.74 Million INR | -5.88% |
| 2022 | 284.45 Million INR | 17.05% |
| 2021 | 243.01 Million INR | 3.94% |
| 2020 | 233.79 Million INR | 93.55% |
| 2019 | 120.79 Million INR | 29.18% |
| 2018 | 93.51 Million INR | -18.67% |
| 2017 | 114.97 Million INR | -7.3% |
| 2016 | 124.02 Million INR | -56.19% |
| 2015 | 283.07 Million INR | -62.07% |
| 2014 | 746.41 Million INR | -2.77% |
| 2013 | 767.69 Million INR | -16.37% |
| 2012 | 917.92 Million INR | 41.41% |
| 2011 | 649.12 Million INR | 6.61% |
| 2010 | 608.88 Million INR | -50.68% |
| 2009 | 1.23 Billion INR | -1.4% |
| 2008 | 1.25 Billion INR | 10.91% |
| 2007 | 1.12 Billion INR | 34.21% |
| 2006 | 841.14 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 238.92 Million INR | 0.0% |
| 2023 Q2 | 279.68 Million INR | 0.0% |
| 2023 Q4 | 267.74 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 267.74 Million INR | -5.88% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 284.45 Million INR | 0.0% |
| 2022 Q2 | 221.5 Million INR | 0.0% |
| 2022 FY | 284.45 Million INR | 17.05% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 243.01 Million INR | 3.94% |
| 2021 Q4 | 243.01 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 217.17 Million INR | 0.0% |
| 2020 Q4 | 233.79 Million INR | 0.0% |
| 2020 FY | 233.79 Million INR | 93.55% |
| 2020 Q2 | 211.84 Million INR | 0.0% |
| 2019 Q4 | 120.79 Million INR | 0.0% |
| 2019 FY | 120.79 Million INR | 29.18% |
| 2019 Q2 | 75.03 Million INR | 0.0% |
| 2018 Q4 | 93.51 Million INR | 0.0% |
| 2018 FY | 93.51 Million INR | -18.67% |
| 2017 FY | 114.97 Million INR | -7.3% |
| 2017 Q4 | 114.97 Million INR | 0.0% |
| 2017 Q2 | 168.24 Million INR | 0.0% |
| 2016 FY | 124.02 Million INR | -56.19% |
| 2016 Q4 | 415.64 Million INR | 0.0% |
| 2016 Q2 | 550.4 Million INR | 0.0% |
| 2015 FY | 283.07 Million INR | -62.07% |
| 2015 Q2 | 701.63 Million INR | 0.0% |
| 2015 Q4 | 283.07 Million INR | 0.0% |
| 2014 Q4 | 746.41 Million INR | 0.0% |
| 2014 FY | 746.41 Million INR | -2.77% |
| 2013 FY | 767.69 Million INR | -16.37% |
| 2012 FY | 917.92 Million INR | 41.41% |
| 2012 Q4 | 917.92 Million INR | 0.0% |
| 2012 Q2 | 1.27 Billion INR | 0.0% |
| 2011 FY | 649.12 Million INR | 6.61% |
| 2010 FY | 608.88 Million INR | -50.68% |
| 2009 FY | 1.23 Billion INR | -1.4% |
| 2008 FY | 1.25 Billion INR | 10.91% |
| 2007 FY | 1.12 Billion INR | 34.21% |
| 2006 FY | 841.14 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 57.42% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.746% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -81.383% |
| Granules India Limited | 689.71 Million INR | 61.181% |
| Indoco Remedies Limited | 3.51 Billion INR | 92.388% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -13.835% |
| Alkem Laboratories Limited | 400 Million INR | 33.065% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -7410.238% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -861.848% |
| Bajaj HealthCare Limited | 650.34 Million INR | 58.831% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 24.776% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 95.53% |
| Eris Lifesciences Limited | 6.54 Billion INR | 95.909% |
| FDC Limited | 2.46 Million INR | -10757.259% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 82.35% |
| Gufic Biosciences Limited | 1.53 Billion INR | 82.61% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -139.855% |
| Ipca Laboratories Limited | 5.8 Billion INR | 95.387% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -254.294% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 85.409% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 96.888% |
| Lupin Limited | 1.55 Billion INR | 82.758% |
| Mankind Pharma Limited | 248.67 Million INR | -7.666% |
| Medicamen Biotech Limited | 12.55 Million INR | -2032.537% |
| Medico Remedies Limited | 8.67 Million INR | -2987.408% |
| Megasoft Limited | 1.35 Billion INR | 80.271% |
| NATCO Pharma Limited | 53 Million INR | -405.17% |
| Piramal Pharma Limited | 24.83 Billion INR | 98.922% |
| RPG Life Sciences Limited | -30.3 Million INR | 983.63% |
| Sigachi Industries Limited | 265.79 Million INR | -0.731% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -1913.083% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -26.081% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 22063.905% |
| Unichem Laboratories Limited | 382.22 Million INR | 29.952% |
| Wanbury Limited | 820 Million INR | 67.349% |
| Windlas Biotech Limited | 20.18 Million INR | -1226.759% |
| ZIM Laboratories Limited | 356 Million INR | 24.793% |
| Zydus Lifesciences Limited | 251 Million INR | -6.669% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -151.163% |
| Divi's Laboratories Limited | 20 Million INR | -1238.7% |
| Hester Biosciences Limited | 1.81 Billion INR | 85.271% |
| Procter & Gamble Health Limited | 68.8 Million INR | -289.157% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -1816.81% |
| Bal Pharma Limited | 363.82 Million INR | 26.409% |
| Strides Pharma Science Limited | 6.71 Billion INR | 96.013% |
| Venus Remedies Limited | 386.8 Million INR | 30.781% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -66835.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 80.918% |
| Shilpa Medicare Limited | 5.6 Billion INR | 95.22% |
| Aarti Drugs Limited | 2.75 Billion INR | 90.276% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 97.348% |
| Valiant Laboratories Limited | 746.63 Million INR | 64.14% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -13.257% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 74.701% |
| Hikal Limited | 4.22 Billion INR | 93.668% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 98.331% |
| Sequent Scientific Limited | 1.42 Billion INR | 81.24% |
| Novartis India Limited | 50.7 Million INR | -428.087% |
| Wockhardt Limited | 8.91 Billion INR | 96.995% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.155% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 40.397% |
| Morepen Laboratories Limited | 33.64 Million INR | -695.898% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -100.493% |